Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Emboliner

Cardiovascular

Cardiovascular Today—April 2, 2026

This week’s Cardiovascular update highlights regulatory approvals, device…

Cardiovascular

Cardiovascular Today—March 19, 2026

This week’s Cardiovascular update highlights clinical trial progress, product…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: UCB acquisition of Candid Therapeutics
Hematology Today—May 4, 2026
Oncology Today—May 4, 2026
AI in Healthcare and Digital Health Today—May 4, 2026
Lucid Diligence Brief: Axoft $55 million Series A

Tags

AAV MYO2 ART5803 B7-H3 Bulumtatug Fuvedotin CanSino cardiovascular risk factors Cas12 cladribine Corcept cutaneous T-cell lymphoma cytomegalovirus Dapagliflozin data linkage Dexcom Efimosfermin Evkeeza FSHD G-CROWN Global Burden of Disease Hanmi HM17321 HealthBench Professional heart failure congestion infectious disease diagnostics Kisunla MannKind Miltenyi Bioindustry multispecific antibodies Nature Immunology Neural Drive neurological epidemiology Non-ST-Elevation Myocardial Infarction PANTHERx Rare personalized cancer vaccine Redx Pharma risperidone LAI Saudi Arabia Systemic lupus erythematosus Tovorafenib TYK2 inhibitor UnitedHealthcare UZEDY Vaccines Research Vevzuo WINREVAIR Yashoda

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: UCB acquisition of Candid Therapeutics
Hematology Today—May 4, 2026
Oncology Today—May 4, 2026
AI in Healthcare and Digital Health Today—May 4, 2026
Lucid Diligence Brief: Axoft $55 million Series A

TAGS

AAV MYO2 ART5803 B7-H3 Bulumtatug Fuvedotin CanSino cardiovascular risk factors Cas12 cladribine Corcept cutaneous T-cell lymphoma cytomegalovirus Dapagliflozin data linkage Dexcom Efimosfermin Evkeeza FSHD G-CROWN Global Burden of Disease Hanmi HM17321 HealthBench Professional heart failure congestion infectious disease diagnostics Kisunla MannKind Miltenyi Bioindustry multispecific antibodies Nature Immunology Neural Drive neurological epidemiology Non-ST-Elevation Myocardial Infarction PANTHERx Rare personalized cancer vaccine Redx Pharma risperidone LAI Saudi Arabia Systemic lupus erythematosus Tovorafenib TYK2 inhibitor UnitedHealthcare UZEDY Vaccines Research Vevzuo WINREVAIR Yashoda

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy